This proposal is meant to assist Dr. Lesinski in his transition to becoming an independent investigator in human cancer research. Dr. Lesinski joined the Department of Molecular Virology, Immunology and Medical Genetics at The Ohio State University as an Assistant Professor on the Research Track in 2005. This three year proposal consists of a Career Development Plan designed to further enhance his ability to conduct cancer research in collaboration with clinicians. Dr. Lesinski will continue his education through involvement in various educational seminars, workshops and participation in national scientific meetings. Importantly, he will gain extensive training in the responsible conduct of clinical research, and will complete the didactic requirements to obtain a formal Master of Public Health in Clinical Investigation. Included in this proposal is a Research Plan that extends Dr. Lesinski's prior experience in immunology and oncology into novel studies that investigate how the immune system can mediate cancer control in the setting of malignant melanoma. Specifically, Dr. Lesinski will study how immunosuppressive cytokines act to inhibit the ability of immune cells to control the development of melanoma. It has previously been established that a separate group of immunostimulatory cytokines (e.g., the interferons) are critical for cancer immunosurveillance by host immune cells. The action of interferons can be negatively regulated by a group of proteins termed the """"""""Suppressors of Cytokine Signaling"""""""" or SOCS proteins. It is hypothesized that cytokines present in the tumor microenvironment function by upregulating SOCS proteins within immune cells, making them less responsive to the cytokines that mediate immunosurveillance. Dr. Lesinski will utilize lymph node biopsies from melanoma patients to determine whether the immunosuppressive cytokines present in the tumor microenvironment lead to increased expression of SOCS proteins within immune cells, and inhibit their ability to control the development of malignant melanoma. This research is novel because it will allow for new strategies to harness the full potential of the immune system against early-stage cancer. Thus, effectively turning the immune system against micrometastatic disease is relevant to public health because it represents a promising means of reducing cancer incidence, mortality and morbidity. The data obtained from these initial studies will be used to prepare an R01 grant application focused on mechanisms of immune-mediated cancer control within two years of the K22 award. The Ohio State University's NCI designated Comprehensive Cancer Center (OSU CCC) provides the ideal location for this training. The institution is committed towards the development of Dr. Lesinski, and fully supports his decision to devote 75% of his time towards this goal. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Career Transition Award (K22)
Project #
1K22CA134551-01
Application #
7510255
Study Section
Subcommittee G - Education (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
2008-09-01
Project End
2011-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$148,770
Indirect Cost
Name
Ohio State University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Martin del Campo, Sara E; Levine, Kala M; Mundy-Bosse, Bethany L et al. (2015) The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. J Immunol 195:1995-2005
Yang, Jennifer; Bill, Matthew A; Young, Gregory S et al. (2014) Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One 9:e102983
Mace, Thomas A; Ameen, Zeenath; Collins, Amy et al. (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73:3007-18
Nicholas, Courtney; Yang, Jennifer; Peters, Sara B et al. (2013) PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.). PLoS One 8:e74710
Bill, Matthew A; Nicholas, Courtney; Mace, Thomas A et al. (2012) Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One 7:e40724
Sullivan, Nicholas J; Tober, Kathleen L; Burns, Erin M et al. (2012) UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. J Invest Dermatol 132:695-702
Mundy-Bosse, Bethany L; Young, Gregory S; Bauer, Todd et al. (2011) Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4? T cells from patients with GI malignancy. Cancer Immunol Immunother 60:1269-79
Mundy-Bosse, Bethany L; Lesinski, Gregory B; Jaime-Ramirez, Alena C et al. (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71:5101-10
Guenterberg, Kristan D; Lesinski, Gregory B; Mundy-Bosse, Bethany L et al. (2011) Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4? and CD8? T cells. Cancer Immunol Immunother 60:1281-8
Grignol, V; Fairchild, E T; Zimmerer, J M et al. (2011) miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br J Cancer 105:1023-9

Showing the most recent 10 out of 17 publications